MUC1 aptamer-functionalized chitosan nanoparticles: Targeted delivery platforms for synergistic cancer therapy and multidrug resistance overcoming
- 25 June 2025
- journal article
- review article
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 319 (Pt 4) , 145514
Abstract
No abstract availableKeywords
This publication has 195 references indexed in Scilit:
- Cellular and molecular aspects of drug resistance in cancersDARU Journal of Pharmaceutical Sciences, 2024
- Small molecule– and peptide–drug conjugates addressing integrins: A story of targeted cancer treatmentJournal of Peptide Science, 2024
- Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal AntibodiesBioDrugs, 2024
- Targeted cancer treatment using folate-conjugated sponge-like ZIF-8 nanoparticles: a reviewNaunyn-Schmiedeberg's Archives of Pharmacology, 2023
- Chitosan‐based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapyBioengineering & Translational Medicine, 2022
- The pharmacology and therapeutic applications of monoclonal antibodiesPharmacology Research & Perspectives, 2019
- Anti‐MUC1 aptamer: A potential opportunity for cancer treatmentMedicinal Research Reviews, 2017
- Post-SELEX optimization of aptamersAnalytical and Bioanalytical Chemistry, 2016
- Aptamers and the next generation of diagnostic reagentsProteomics – Clinical Applications, 2012
- Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicityGlycoconjugate Journal, 2012